biblioteca virtual en salud

Búsqueda | Gripe por A(H1N1)

  • BIREME | OPAS | OMS logo
 

Historico de búsqueda  ()

Su selección  ()

 0 documento(s) seleccionado(s).

Refine su búsqueda

Collapse All  Ocultar
Expand All  Mostrar
Áreas temáticas
Texto completo (407)
Idioma
Año

Enviar por email

Ud. tiene 0 documento(s) seleccionado(s).

Ningún documento seleccionado

 
Resultados  1-12 de 618
1.

1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.

Autor(es): Geisman AN; Valuev-Elliston VT; Ozerov AA; Khandazhinskaya AL; Chizhov AO; Kochetkov SN; Pannecouque C; Naesens L; Seley-Radtke KL; Novikov MS
Fuente: Bioorg Med Chem;24(11): 2476-85, 2016 Jun 1.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27112451
Resumen: A series of 1,6-bis[(benzyloxy)methyl]uracil derivatives combining structural features of both diphenyl ether and pyridone types of NNRTIs were synthesized. Target compounds were found to inhibit HIV-1 reverse transcriptase at micro- and submicromolar levels of concentrations and exhibited anti-HIV-1 activity in MT-4 cell culture, demonstrating resistance profile similar to first generation NNRTIs. The synthesized compounds also showed profound activity against influenza virus (H1N1) in MDC (mas)
2.

In vitro and in vivo mechanism of immunomodulatory and antiviral activity of Edible Bird's Nest (EBN) against influenza A virus (IAV) infection.

Autor(es): Haghani A; Mehrbod P; Safi N; Aminuddin NA; Bahadoran A; Omar AR; Ideris A
Fuente: J Ethnopharmacol;185: 327-40, 2016 Jun 5.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26976767
Resumen: ETHNOPHARMACOLOGICAL RELEVANCE: For centuries, Edible Bird Nest (EBN) has been used in treatment of variety of respiratory diseases such as flu and cough as a Chinese natural medicine. AIM OF THE STUDY: This natural remedy showed the potential to inhibit influenza A virus (IAV). However, little is known about the mechanism of this process and also the evaluation of this product in an animal model. Hence, the current study was designed to elucidate the antiviral and immunomodulatory effects (mas)
3.

Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease.

Autor(es): Pillai PS; Molony RD; Martinod K; Dong H; Pang IK; Tal MC; Solis AG; Bielecki P; Mohanty S; Trentalange M; Homer RJ; Flavell RA; Wagner DD; Montgomery RR; Shaw AC; Staeheli P; Iwasaki A
Fuente: Science;352(6284): 463-6, 2016 Apr 22.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 27102485
Resumen: Influenza A virus (IAV) causes up to half a million deaths worldwide annually, 90% of which occur in older adults. We show that IAV-infected monocytes from older humans have impaired antiviral interferon production but retain intact inflammasome responses. To understand the in vivo consequence, we used mice expressing a functional Mx gene encoding a major interferon-induced effector against IAV in humans. In Mx1-intact mice with weakened resistance due to deficiencies in Mavs and Tlr7, we f (mas)
4.

Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.

Autor(es): Ruangrung K; Suptawiwat O; Maneechotesuwan K; Boonarkart C; Chakritbudsabong W; Assawabhumi J; Bhattarakosol P; Uiprasertkul M; Puthavathana P; Wiriyarat W; Jongkaewwattana A; Auewarakul P
Fuente: J Virol;90(9): 4637-46, 2016 May 1.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26912622
Resumen: UNLABELLED: Human bronchoalveolar fluid is known to have anti-influenza activity. It is believed to be a frontline innate defense against the virus. Several antiviral factors, including surfactant protein D, are believed to contribute to the activity. The 2009 pandemic H1N1 influenza virus was previously shown to be less sensitive to surfactant protein D. Nevertheless, whether different influenza virus strains have different sensitivities to the overall anti-influenza activity of human bron (mas)
5.

Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.

Autor(es): Yu J; Wang D; Jin J; Xu J; Li M; Wang H; Dou J; Zhou C
Fuente: Antiviral Res;127: 68-78, 2016 Mar.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26802558
Resumen: A target-free and cell-based approach was applied to evaluate the anti-influenza properties of six newly synthesized benzoic acid derivatives. SA-2, the ethyl 4-(2-hydroxymethyl-5-oxopyrrolidin-1-yl)-3-[3-(3-methylbenzoyl)-thioureido] benzoate (compound 2) was screened as a potential drug candidate. In a cytopathic effect assay, SA-2 dose dependently inhibited H1N1, H3N2 and the oseltamivir-resistant mutant H1N1-H275Y influenza viruses in both virus-infected MDCK and A549 cells, with 50% e (mas)
6.

Influenza virus surveillance in Argentina during the 2012 season: antigenic characterization, genetic analysis and antiviral susceptibility.

Autor(es): Benedetti E; Daniels RS; Pontoriero A; Russo M; Avaro M; Czech A; Campos A; Periolo N; Gregory V; McCAULEY JW; Baumeister EG
Fuente: Epidemiol Infect;144(4): 751-67, 2016 Mar.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26345289
Resumen: The activity and circulation of influenza viruses in Argentina was studied during 2012 as part of the Argentinean Surveillance for Influenza and other Respiratory Viruses, in the context of Global Influenza Surveillance. The antigenicity and molecular characteristics of haemagglutinins (HA) of circulating influenza A and B viruses were analysed to assess the emergence of virus variants. Susceptibility to oseltamivir and zanamivir was evaluated by enzymatic assay and results were backed-up b (mas)
7.

Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model.

Autor(es): Fullen DJ; Noulin N; Catchpole A; Fathi H; Murray EJ; Mann A; Eze K; Balaratnam G; Borley DW; Gilbert A; Lambkin-Williams R
Fuente: PLoS One;11(1): e0145902, 2016.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26761707
Resumen: BACKGROUND: Influenza and its associated diseases are a major cause of morbidity and mortality. The United States Advisory Committee on Immunization Practices recommends influenza vaccination for everyone over 6 months of age. The failure of the flu vaccine in 2014-2015 demonstrates the need for a model that allows the rapid development of novel antivirals, universal/intra-seasonal vaccines, immunomodulators, monoclonal antibodies and other novel treatments. To this end we manufactured a ne (mas)
8.

Discovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous Heterosubtypic Targeting that Hedge against Antiviral Resistance.

Autor(es): Wee KB; Lee RT; Lin J; Pramono ZA; Maurer-Stroh S
Fuente: PLoS Comput Biol;12(1): e1004663, 2016 Jan.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26771381
Resumen: The multiple circulating human influenza A virus subtypes coupled with the perpetual genomic mutations and segment reassortment events challenge the development of effective therapeutics. The capacity to drug most RNAs motivates the investigation on viral RNA targets. 123,060 segment sequences from 35,938 strains of the most prevalent subtypes also infecting humans-H1N1, 2009 pandemic H1N1, H3N2, H5N1 and H7N9, were used to identify 1,183 conserved RNA target sequences (≥15-mer) in th (mas)
9.

Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry.

Autor(es): Wu W; Li R; Li X; He J; Jiang S; Liu S; Yang J
Fuente: Viruses;8(1)2016 Jan.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26712783
Resumen: Influenza A viruses (IAVs) cause seasonal pandemics and epidemics with high morbidity and mortality, which calls for effective anti-IAV agents. The glycoprotein hemagglutinin of influenza virus plays a crucial role in the initial stage of virus infection, making it a potential target for anti-influenza therapeutics development. Here we found that quercetin inhibited influenza infection with a wide spectrum of strains, including A/Puerto Rico/8/34 (H1N1), A/FM-1/47/1 (H1N1), and A/Aichi/2/68 (mas)
10.

[Antiviral effects of the combination of glycyrrhizin and ribavirin against influenza A H1N1 virus infection in vivo].

Autor(es): Chen XX; Zhou HX; Qi WB; Ning ZY; Ma YJ; Li YL; Wang GC; Chen JX
Fuente: Yao Xue Xue Bao;50(8): 966-72, 2015 Aug.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26668995
Resumen: Ribavirin is a broad-spectrum antiviral agent and glycyrrhizin has activities of anti-inflammation, immunoregulation and anti-viral infections. To enhance antiviral efficacy and weaken side-effects of ribavirin, antiviral effects of the combination of glycyrrhizin and ribavirin were studied in the present study. Firstly, a mouse model of viral pneumonia was established by inoculation of influenza H1N1 virus. Protective effects of glycyrrhizin and ribavirin used alone or in combination again (mas)
12.

Oligomerization and GTP-binding Requirements of MxA for Viral Target Recognition and Antiviral Activity against Influenza A Virus.

Autor(es): Nigg PE; Pavlovic J
Fuente: J Biol Chem;290(50): 29893-906, 2015 Dec 11.
MEDLINE - Literatura Internacional en Ciencias de la Salud PMID: 26507657
Resumen: The IFN-induced human myxovirus resistance protein A (MxA) exhibits a broad antiviral activity against many viruses, including influenza A virus (IAV). MxA belongs to the family of dynamin-like GTPases and assembles in vitro into dimers, tetramers, and oligomeric ring-like structures. The molecular mechanism of action remains to be elucidated. Furthermore, it is not clear whether MxA exerts its antiviral activity in a monomeric and/or multimeric form. Using a set of MxA mutants that form co (mas)
Resultados  1-12 de 618